The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Subclinical Thyroid Dysfunction and Fracture Risk: A Meta-analysis
Open accessAbstract
IMPORTANCE: Associations between subclinical thyroid dysfunction and fractures are unclear and clinical trials are lacking. OBJECTIVE: To assess the association of subclinical thyroid dysfunction with hip, nonspine, spine, or any fractures. DATA SOURCES AND STUDY SELECTION: The databases of MEDLINE and EMBASE (inception to March 26, 2015) were searched without language restrictions for prospective cohort studies with thyroid function data and subsequent fractures. DATA EXTRACTION: Individual participant data were obtained from 13 prospective cohorts in the United States, Europe, Australia, and Japan. Levels of thyroid function were defined as euthyroidism (thyroid-stimulating hormone [TSH], 0.45-4.49 mIU/L), subclinical hyperthyroidism (TSH <0.45 mIU/L), and subclinical hypothyroidism (TSH ≥4.50-19.99 mIU/L) with normal thyroxine concentrations. MAIN OUTCOME AND MEASURES: The primary outcome was hip fracture. Any fractures, nonspine fractures, and clinical spine fractures were secondary outcomes. RESULTS: Among 70,298 participants, 4092 (5.8%) had subclinical hypothyroidism and 2219 (3.2%) had subclinical hyperthyroidism. During 762,401 person-years of follow-up, hip fracture occurred in 2975 participants (4.6%; 12 studies), any fracture in 2528 participants (9.0%; 8 studies), nonspine fracture in 2018 participants (8.4%; 8 studies), and spine fracture in 296 participants (1.3%; 6 studies). In age- and sex-adjusted analyses, the hazard ratio (HR) for subclinical hyperthyroidism vs euthyroidism was 1.36 for hip fracture (95% CI, 1.13-1.64; 146 events in 2082 participants vs 2534 in 56,471); for any fracture, HR was 1.28 (95% CI, 1.06-1.53; 121 events in 888 participants vs 2203 in 25,901); for nonspine fracture, HR was 1.16 (95% CI, 0.95-1.41; 107 events in 946 participants vs 1745 in 21,722); and for spine fracture, HR was 1.51 (95% CI, 0.93-2.45; 17 events in 732 participants vs 255 in 20,328). Lower TSH was associated with higher fracture rates: for TSH of less than 0.10 mIU/L, HR was 1.61 for hip fracture (95% CI, 1.21-2.15; 47 events in 510 participants); for any fracture, HR was 1.98 (95% CI, 1.41-2.78; 44 events in 212 participants); for nonspine fracture, HR was 1.61 (95% CI, 0.96-2.71; 32 events in 185 participants); and for spine fracture, HR was 3.57 (95% CI, 1.88-6.78; 8 events in 162 participants). Risks were similar after adjustment for other fracture risk factors. Endogenous subclinical hyperthyroidism (excluding thyroid medication users) was associated with HRs of 1.52 (95% CI, 1.19-1.93) for hip fracture, 1.42 (95% CI, 1.16-1.74) for any fracture, and 1.74 (95% CI, 1.01-2.99) for spine fracture. No association was found between subclinical hypothyroidism and fracture risk. CONCLUSIONS AND RELEVANCE: Subclinical hyperthyroidism was associated with an increased risk of hip and other fractures, particularly among those with TSH levels of less than 0.10 mIU/L and those with endogenous subclinical hyperthyroidism. Further study is needed to determine whether treating subclinical hyperthyroidism can prevent fractures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, the data reported in the available prospective cohort studies suggest an increased risk of hip fractures and non-spine fractures in SHyper, with the risk of fractures being greater in adults with grade 2 SHyper [108, 109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 2 SHyper was associated with higher fracture rates with an HR of 1.61 (95% CI: 1.21-2.15;47 events in 510 participants) for hip fracture, 1.98 (95% CI: 1.41-2.78;44 events in 212 participants) for any fracture, 1.61 (95% CI: 0.96-2.71;32 events in 185 participants) for non-spine fracture and 3.57 (95% CI: 1.88-6.78;8 events in 162 participants) for spine fracture [109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these meta-analyses do not show evidence that treatment is effective in improving the risks associated with untreated SHyper, they demonstrate that SHyper is a potentially life-threatening condition.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data, however, indicate that subclinical hyperthyroidism is associated with low bone mineral density (BMD) and an increased risk of fracture.”
From Thyroid diseases and bone health (2018) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, subclinical hyperthyroidism was associated with bone loss and fracture, particularly in individuals with endogenous disease [28].”
From Thyroid diseases and bone health (2018) · cites this paper as [28]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large-scale cohort studies and meta-analyses have reported an increased risk of osteoporosis and osteoporotic fractures, so there is much convincing evidence that asymptomatic endogenous hyperthyroidism adversely affects bones (14,39).”
From Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A very recent meta-analysis, including IPD from 13 prospective cohorts, confirmed that Endo SHyper is associated with an increased risk of fractures with an HR of 1.52 (95% CI: 1.19-1.93)for hip fracture, 1.42 (95% CI: 1.16-1.74)for any fracture and 1.74 (95% CI: 1.01-2.99)for spine fracture [109].”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“A very recent meta-analysis, including IPD from 13 prospective cohorts, confirmed that Endo SHyper is associated with an increased risk of fractures with an HR of 1.52 (95% CI: 1.19-1.93)for hip fracture, 1.42 (95% CI: 1.16-1.74)for any fracture and 1.74 (95% CI: 1.01-2.99)for spine fracture [109].”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Grade 2 SHyper was associated with higher fracture rates with an HR of 1.61 (95% CI: 1.21-2.15;47 events in 510 participants) for hip fracture, 1.98 (95% CI: 1.41-2.78;44 events in 212 participants) for any fracture, 1.61 (95% CI: 0.96-2.71;32 events in 185 participants) for non-spine fracture and 3.57 (95% CI: 1.88-6.78;8 events in 162 participants) for spine fracture [109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Grade 2 SHyper was associated with higher fracture rates with an HR of 1.61 (95% CI: 1.21-2.15;47 events in 510 participants) for hip fracture, 1.98 (95% CI: 1.41-2.78;44 events in 212 participants) for any fracture, 1.61 (95% CI: 0.96-2.71;32 events in 185 participants) for non-spine fracture and 3.57 (95% CI: 1.88-6.78;8 events in 162 participants) for spine fracture [109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Grade 2 SHyper was associated with higher fracture rates with an HR of 1.61 (95% CI: 1.21-2.15;47 events in 510 participants) for hip fracture, 1.98 (95% CI: 1.41-2.78;44 events in 212 participants) for any fracture, 1.61 (95% CI: 0.96-2.71;32 events in 185 participants) for non-spine fracture and 3.57 (95% CI: 1.88-6.78;8 events in 162 participants) for spine fracture [109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“A very recent meta-analysis, including IPD from 13 prospective cohorts, confirmed that Endo SHyper is associated with an increased risk of fractures with an HR of 1.52 (95% CI: 1.19-1.93)for hip fracture, 1.42 (95% CI: 1.16-1.74)for any fracture and 1.74 (95% CI: 1.01-2.99)for spine fracture [109].”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Grade 2 SHyper was associated with higher fracture rates with an HR of 1.61 (95% CI: 1.21-2.15;47 events in 510 participants) for hip fracture, 1.98 (95% CI: 1.41-2.78;44 events in 212 participants) for any fracture, 1.61 (95% CI: 0.96-2.71;32 events in 185 participants) for non-spine fracture and 3.57 (95% CI: 1.88-6.78;8 events in 162 participants) for spine fracture [109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“A very recent meta-analysis, including IPD from 13 prospective cohorts, confirmed that Endo SHyper is associated with an increased risk of fractures with an HR of 1.52 (95% CI: 1.19-1.93)for hip fracture, 1.42 (95% CI: 1.16-1.74)for any fracture and 1.74 (95% CI: 1.01-2.99)for spine fracture [109].”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Three recent meta-analyses provide evidence, based also on IPD data, for treating SHyper with undetectable TSH because of an excess risk of total mortality, CHD mortality, HF, incident AF and fractures among adults with grade 2 SHyper [71,75,108,109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
The cited source says what the claim attributes to it.
In the citing paper
“Although these meta-analyses do not show evidence that treatment is effective in improving the risks associated with untreated SHyper, they demonstrate that SHyper is a potentially life-threatening condition.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [109]
In the citing paper
“A recent participant-level meta-analysis of 13 cohorts (70,298 participants, median follow-up of 12.1 years) con-cluded that SH subjects had significantly elevated hazard ratios of 1.36 for hip fractures (6 vs. 4.9 fractures per 1000 person-years) and 1.28 for any fractures (14.4 vs. 11.2fractures per 1000 person-years) (413).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2014) · Medical Entomology and Zoology · Cited by 17,633
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
Systematic Reviews in Health Care: Meta‐analysis in Context
Pittler, M. (2010) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05479.x · Cited by 1,639
Flagged first, then by citations
Research works printed but not linked: 1
- [13]BMJ Clinical Evidence Search filters (Medline cohort study filter): ClinicalEvidence website 2013 http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html Accessed May 5, 2015
Cited by
Sorted by citations
Items 301–343 of 343
Fu, Y., Zhang, H., Xu, K., & Zhao, M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4175923
ПАТОЛОГІЯ ЩИТОПОДІБНОЇ ЗАЛОЗИ У ПАЦІЄНТОК ІЗ РЕПРОДУКТИВНИМИ ВТРАТАМИ ТА ГІПЕРПЛАЗІЄЮ ЕНДОМЕТРІЯ
Orishchak, I. (2022) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2021.2.12763
Tessnow, A. H. (2022) · Clinical Thyroidology · doi:10.1089/ct.2022;34.385-388
Lademann, F., Rauner, M., & Tsourdi, E. A. (2022) · Osteologie/Osteology · doi:10.1055/a-1951-1233
Modification of TSH-related genetic effects by indicators of socioeconomic position
Drogge, S.-C., Frank, M., Girschik, C., Jöckel, K., Führer‐Sakel, D., & Schmidt, B. (2022) · Endocrine Connections · doi:10.1530/ec-22-0127
Netea-Maier, R. T. (2021) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2707-2_20
The Role of Thyroid Hormones on Management of Cartilaginous Joint Disorders
Azzini, G. O. M., Visoni, S. B. C., Santos, G. S., Huber, S. C., de Macedo, A. P., Ingrao, I. L. G., & Lana, J. F. (2018) · doi:10.19080/ntab.2018.03.555611
Stijgend gebruik van levothyroxine in België
Boets, L., den Bruel, A. V., haecht, C. V., Cornelis, K., Debbaut, B., Ntahonganyira, R.-M., Flamaing, J., Stokx, J., & Decallonne, B. (2024) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.122
Shen, Y., Xiong, D., Zhou, H., Wang, X., Zhao, T., Li, X., Sun, M., Yu, S., Huang, X., Cao, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4388105/v1
L-Thyroxin bei Hypothyreose – absetzen oder nicht?
Kramer, M. R., Bleckwenn, M., Deutsch, T., Voigt, K., & Schübel, J. (2024) · Zeitschrift für Allgemeinmedizin · doi:10.1007/s44266-024-00291-9
Langdahl, B. L., & Grove‐Laugesen, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00080-7
Shang, Z., Fang, C., Lang, X., & Zhang, X. (2024) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2024.10.003
la Torre, M. Z.-D., Bolaños-Cacho-Casillas, D., Clara-Altamirano, M., & Álvarez, J. M. N. (2025) · Acta Ortopédica Mexicana · doi:10.35366/118851
Maushart, C. I., & Betz, M. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00248-x
Zhao, B., Zhong, Q., & Liu, X. (2025) · Medicine · doi:10.1097/md.0000000000042856
Magnitude of thyroid disorders: Global epidemic and Bangladesh perspective
Siddiqui, M. N. I. (2025) · Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh · doi:10.3329/jacedb.v2i2.78439
Svensson, J., Ohlsson, C., Karlsson, M. K., Tivesten, Å., Herlitz, H., Lorentzon, M., Lewerin, C., & Mellström, D. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf121
Assessment of periostin in postmenopausal thyroid patients: A prospective case-control study
Gupta, A. K., Faruqui, S., & Jha, A. N. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100270
Lv, H., Yang, X., Zhang, R., Xie, Y., Ni, X., Yang, X., & Shi, B. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673362752250730045645
Radiological Evaluation of Bone Findings in Endocrine Disorders
Cingöz, E., & Dursun, M. (2025) · Türk Radyoloji Seminerleri · doi:10.4274/trs.2025.25198
Pisano, S., & Cusini, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_12
Deng, T., Zhang, W., Zhang, Y., Zhang, M., Huan, Z., Yu, C., Zhang, X., Wang, Y., & Xu, J. (2021) · Figshare · doi:10.6084/m9.figshare.14228503
Rallapalli, S. S., Cherian, K. E., Hephzibah, J., Jebasingh, F., Kapoor, N., Asha, H., Thomas, N., & Paul, T. V. (2026) · Calcified Tissue International · doi:10.1007/s00223-025-01472-9
Thyroid disorders in the elderly
Tzoraki, M., & Duntas, L. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00299-5
Iodine for Health and Longevity
Riis, J., Thomsen, M. J., Andersen, S. L., & Andersen, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-11608-6_7
Yamaya, A. C., Ward, L. S., Cury, A. N., Scalissi, N. M., Silva, C. F., Santos, L. M., & Padovani, R. D. P. (2026) · Research Square · doi:10.21203/rs.3.rs-8767986/v1
TSH suppression attenuates the early efficacy of zoledronic acid in osteoporosis
Liu, Y., Zhang, Y., Li, M., Qian, Y., Zhang, Z., Jiang, Z., & Qu, W. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01672-2
Hořák, P. (2025) · Clinical Osteology · doi:10.36290/clo.2025.009
Thyroid and osteoporosis: Pathophysiology, clinical consequences, and management
Ghosh, A., & Sanjeev, K. N. (2026) · Thyroid Research and Practice · doi:10.4103/trp.trp_28_25
Recommendations for the diagnosis, prevention and treatment of osteoporosis in men
Grygorieva, N. V., Корж, М. О., Tronko, M. D., Mankovsky, B. M., Yatsyshyn, R. I., Golovach, I. Y., Страфун, С. С., Сміян, С. І., Gurzhenko, Y. M., Рекалов, Д. Г., et al. (2026) · TRAUMA · doi:10.22141/1608-1706.2.27.2026.1081
Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report
McCarroll, K. G., Carroll, A., Brennan, F., Gargan, D., Fitzpatrick, D., & Lannon, R. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06066-z
Troshina, E. A., Sviridenko, N. Y., Platonova, N. M., Михайловна, Б. И., Шеремета, М. С., Bessmertnaya, E. G., Yanovskaya, E. A., Aleksandrov, Y., Сергеевна, Я. В., & Syrtsova, E. I. (2026) · Clinical and experimental thyroidology · doi:10.14341/ket12839
Soto, R. L., & Cabrera, J. A. B. (2026) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2026.07.004
Endocrine-related osteoporosis: bone quality, clinical phenotype, and targeted management
Cincione, R. I., Marcantonio, R., Monda, M., Polito, R., Casillo, M., Messina, A., Monda, A., Moscatelli, F., Messina, G., & Panico, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1869556
Bjerkreim, B. A., Hammerstad, S. S., Lee-Ødegård, S., & Eriksen, E. F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1919606
The Underdiagnosed Endocrinopathy: Subclinical Hyperthyroidism and Its Burden in Older Adults
Garg, R. (2026) · South Asian Journal of Geriatric Medicine Surgery Palliative Care & Hospice · doi:10.4103/sajogm.sajogm_27_26
Effects of thyroid hormones on muscle and bone in mice
Nishikawa, A., Kawao, N., Mizukami, Y., Kishigami, R., Goto, K., & Kaji, H. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2937-4838
Subclinical Hyperthyroidism in the Elderly: Small Numbers, Big Consequences
Garg, R. (2026) · Global Journal of Guntur Medical College · doi:10.25259/gjgmc_15_2026
Ghotbi, E., McGready, J., Hadidchi, R., Ibad, H. A., Simonsick, E. M., Xue, Q., Demehri, S., & Mammen, J. S. (2026) · Bone · doi:10.1016/j.bone.2026.118100
Ahn, S. H., Kim, D. W., Kim, J., Kim, K. J., Ha, J., Seo, M., Kim, B., Kim, H.-S., & Hong, E. (2026) · Thyroid · doi:10.1177/10507256261495805
Hantian, Z., Li, M., Lin, D., Yang, L., Yang, Z., Wu, T., Li, Y., & Liu, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1959544
Akbaş, S., Uçkun, A., Gümüşçubuk, O., Yalçın, A., Varlı, M., & Atmış, V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208059
Thyroid Disorders in Older Adults
Pandya, N., Katib, H., & Santiago, L. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2026.09.002
Metadata
- Authors
- Blum, M. R., Bauer, D. C., Collet, T.-H., Fink, H. A., Cappola, A. R., da Costa, B. R., Wirth, C. D., Peeters, R. P., Åsvold, B. O., den Elzen, W. P. J., Luben, R. N., Imaizumi, M., Bremner, A. P., Gogakos, A., Eastell, R., Kearney, P. M., Strotmeyer, E. S., Wallace, E. R., Hoff, M., Ceresini, G., Rivadeneira, F., Uitterlinden, A. G., Stott, D. J., Westendorp, R. G. J., Khaw, K.-T., Langhammer, A., Ferrucci, L., Gussekloo, J., Williams, G. R., Walsh, J. P., Jüni, P., Aujesky, D., & Rodondi, N.
- Affiliations
- University Hospital of Bern (CH)
- University of California, San Francisco (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- University of Minnesota (US)
- University of Pennsylvania Health System (US)
- Department of Physical Therapy, Nicole Wertheim College of Nursing and Health Science, Florida International University, Miami
- Erasmus MC (NL)
- Norwegian University of Science and Technology (NO)
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands
- University of Cambridge (GB)
- Radiation Effects Research Foundation (JP)
- The University of Western Australia (AU)
- Imperial College London (GB)
- University of Sheffield (GB)
- University College Cork (IE)
- University of Pittsburgh (US)
- University of Washington (US)
- Ospedale di Parma (IT)
- University of Glasgow (GB)
- University of Copenhagen (DK)
- National Institutes of Health (US)
- Leiden University Medical Center (NL)
- University of Bern (CH)
- Corresponding author
- Rodondi, Nicolas
- ORCID
- Blum, Manuel R.
- Bauer, Douglas C.
- Collet, Tinh-Hai
- Fink, Howard A.
- Cappola, Anne R.
- Wirth, Christina D.
- Peeters, Robin P.
- Åsvold, Bjørn O.
- Luben, Robert N.
- Bremner, Alexandra P.
- Gogakos, Apostolos
- Eastell, Richard
- Kearney, Patricia M.
- Strotmeyer, Elsa S.
- Wallace, Erin R.
- Hoff, Mari
- Ceresini, Graziano
- Rivadeneira, Fernando
- Uitterlinden, André G.
- Stott, David J.
- Westendorp, Rudi G. J.
- Khaw, Kay-Tee
- Ferrucci, Luigi
- Gussekloo, Jacobijn
- Williams, Graham R.
- Walsh, John P.
- Jüni, Peter
- Aujesky, Drahomir
- Rodondi, Nicolas
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-05-26
- Volume
- 313
- Issue
- 20
- Pages
- 2055
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4729304
- OpenAlex
- W1651572921
- Cited by
- 343
- References
- 71
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 22 · 2023: 28 · 2022: 37 · 2021: 42 · 2020: 45 · 2019: 22 · 2018: 37 · 2017: 23 · 2016: 24 · 2015: 11
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- IRIS (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Science Foundation
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Alexion Pharmaceuticals
- Alere
- University of Pittsburgh
- Norges Teknisk-Naturvitenskapelige Universitet
- Radius Health
- Cancer Research UK
- National Institute for Health and Care Research (NF-SI-0512-10114, UL1TR000128, NF-SI-0513-10073)
- National Osteoporosis Society
- European Commission
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320 030-150 025, 150025, 138267, 145870, 320030, 155318)
- ZonMw
- Fonterra Co-Operative Group
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (911-03-016)
- Schweizerische Herzstiftung
- International Osteoporosis Foundation
- National Institutes of Health (N01-AG-6-2103, n01hc085082-026, n01hc085081-021, n01hc085079-024, UL1TR000128, n01hc085083-027, n01hc085080-026, N01‐AG‐6‐2106, n01hc085086-022, HHSN268200800007C, N01-AG-6-2101, HHSN268201200036C, n01hc055222-001, N01HC85086, N01-HC-85082, N01HC85079, N01HC85080, N01HC85083, N01-HC-85081)
- Canadian Institutes of Health Research
- Medical Research Council (MR/K006312/1)
- Norwegian Institute of Public Health
- National Institute on Aging (N01‐AG‐6–2101, N01HC85081, N01HC85079, U01AG042145, N01-HC-85080, N01-HC-85082, U01AG042168, R01AG028050, N01HC55222, HHSN268200800007C, U01AG042143, U01AG027810, N01-HC-85083, U01AG042139, N01AG62106, U01AG042124, N01HC85083, N01HC85086, U01AG042140, N01‐HC‐85086, R01AG023629, N01-AG-62103, HHSN268201200036C)
- National Heart, Lung, and Blood Institute (N01-HC-85081, N01 HC085086, N01HC-85083, N01 HC085079, N01 HC085083, N01HC85082, N01 HC85086, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01 HC085080, HHSN 268200800007C, N01HC85080, N01AG62101, N01 HC55222, N01AG62106, HHSN268201200036C, N01HC085082, U01HL080295, N01 HC055222, N01AG62103, N01 HC085081, N01-HC85079)
- National Institute of Nursing Research (N01-AG-6–2101, N01-AG-6-2103, N01-AG-6–2106, R01NR012459)
- National Institute of Neurological Disorders and Stroke (N01-AG-6-2106, N01-AG-6-2103, HHSN268200800007C, N01-HC-85080, N01-HC-85083, N01HC85082, N01-AG-6-2101, N01-HC-85081, N01-HC-85086, N01 HC-55222, N01HC85079, HHSN268201200036C)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01AR066160, K24AR051895)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- subclinical thyroid dysfunction, subclinical hyperthyroidism, subclinical hypothyroidism, hip fracture, fracture risk, thyroid-stimulating hormone, spinal fractures, fracture risk factors, bone health, osteoporosis, vitamin D, calcium intake, physical activity, sex differences, age differences, individual patient data meta-analysis, prospective cohort
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Hip Fractures, Humans, Hyperthyroidism, Hypothyroidism, Male, Middle Aged, Risk Factors, Thyrotropin, Spinal Fractures, Fractures, Bone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
